Skip to main navigation Skip to search Skip to main content

A phase 3 open label randomized study of fixed duration pirtobrutinib (LOXO-305) PLUS VENETOCLAS AND RITUXIMAB VS VENETOCLAX & RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date11/11/22 → 11/10/25

Funding

  • Loxo Oncology: $42,460.00